Transaction DateRecipientSharesTypePriceValue
14th September 2020Target N V Biotech200,000Open or private purchase$11.69$2,338,680.00
11th September 2020Target N V Biotech199,029Open or private purchase$11.33$2,255,117.99
8th July 2020Target N V Biotech25,000Open or private purchase$13.21$330,177.50
28th May 2020Daniel Janney6,106Grant/award etc.$0.00
28th May 2020Alan Fuhrman1,221Grant/award etc.$0.00
28th May 2020Antonio M Jr Md D Phil Gotto6,106Grant/award etc.$0.00
28th May 2020Jeffrey Berkowitz6,106Grant/award etc.$0.00
28th May 2020Mark E Mcgovern6,106Grant/award etc.$0.00
28th May 2020Nicole Vitullo6,106Grant/award etc.$0.00
28th May 2020Jay Shepard6,106Grant/award etc.$0.00
Esperion Therapeutics
Esperion Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia.

Ticker: ESPR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1434868
Employees: 193
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $298 M (0%)
Inventory, Net: $8 M (0%)
Assets, Current: $321 M (51%)
Property, Plant and Equipment, Net: $2 M (32%)
Other Assets, Noncurrent: $1 M (2210%)
Assets: $330 M (54%)
Accounts Payable, Current: $30 M (2%)
Liabilities, Current: $84 M (26%)
Liabilities: $245 M (25%)
Common Stock, Value, Issued: $28 Th (3%)
Common Stock, Shares, Issued: $28 M (0%)
Retained Earnings (Accumulated Deficit): $649 M (-6%)
Stockholders' Equity (Parent): $85 M (0%)
Liabilities and Equity: $330 M (54%)
Revenue: $212 M (0%)
Operating Income/Loss: $129 M (136%)
EPS (basic): $4.5 (0%)
EPS (diluted): $4.32 (0%)